孟鲁司特钠治疗小儿哮喘的临床有效性分析(1)
摘 要：目的 研究孟鲁司特钠治疗小儿哮喘的临床有效性。方法 选取2016年10月～2017年11月在我院治疗的120例小儿哮喘，随机分为对照组和观察组，各60例。对照组采用常规对症治疗，观察组采用孟鲁司特钠治疗，对比两组治疗有效率、临床症状消退时间、肺功能指标及不良反应情况。结果 观察组治疗有效率为96.67%，高于对照组的78.33%，差异有统计学意义(P<0.05)。观察组咳嗽、肺部哮鸣音、憋喘消失时间均短于对照组，差异有统计学意义(P<0.05)。观察组VCmax、FEV1、FEV1/FVC改善优于对照组，差异有统计学意义(P<0.05)。在治疗和观察期间，两组患儿均未发生严重不良反应。结论 孟鲁司特钠治疗小儿哮喘疗效显著，可缩短患儿临床症状消退时间，改善患儿肺功能，值得临床推广和应用。
关键词：孟鲁司特钠；小儿哮喘；肺功能指标
中图分类号：R725.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.09.043
, http://www.100md.com
文章编号：1006-1959(2018)09-0138-02
Abstract：Objective To study the clinical efficacy of montelukast sodium in treating asthma in children.Methods 120 children with asthma treated in our hospital from October 2016 to November 2017 were randomly divided into control group and observation group， 60 cases each.The control group was treated with routine symptomatic treatment.The observation group was treated with montelukast sodium.The efficacy of the two groups was compared， the clinical symptoms disappeared，the lung function indicators and adverse reactions were compared.Results The effective rate was 96.67% in the observation group，which was 78.33% higher than that in the control group，the difference was statistically significant(P<0.05).The cough in the observation group， the wheezing of the lungs，and the disappearance of asthma were all shorter than those in the control group，the difference was statistically significant(P<0.05).The observation group VCmax，FEV1，FEV1/FVC improved better than the control group，the difference was statistically significant(P<0.05). During the treatment and observation period，no serious adverse reactions occurred in both groups of children.Conclusion Montelukast sodium is effective in the treatment of children with asthma.It can shorten the time of clinical symptoms and improve the lung function of children.It is worthy of clinical promotion and application.
, 百拇医药
Key words：Montelukast sodium；Children with asthma；Lung function index
哮喘(asthma)是由炎癥因子等多种原因引起的变态性反应，是小儿常见的呼吸道疾病[1]。临床患儿多伴有胸闷、喘息、咳嗽等症状，严重影响患儿的健康和生活质量。小儿哮喘急性发作时患儿会出现严重呼吸困难，且该疾病容易反复，影响患儿的健康生长，临床应给予有效治疗。小儿哮喘的常规治疗采用止咳、平喘等对症治疗，临床效果有限，治疗疗程长。有关研究表明，采用孟鲁司特钠治疗小儿哮喘具有理想的治疗效果[2]。本次研究选取2016年10月～2017年11月在我院治疗的120例小儿哮喘临床资料，分析孟鲁司特钠治疗小儿哮喘的临床有效性，现报告如下。
1资料与方法
1.1一般资料 回顾分析2016年10月～2017年11月在重庆市丰都县中医院治疗的120例小儿哮喘临床资料。按照随机数字表法分为对照组和观察组，每组60例。对照组中，男34例，女26例；年龄3～14岁，平均年龄(5.98±2.10)岁；病程2～8年，平均病程(2.34±0.40)年。观察组中，男32例，女28例；年龄2～14岁，平均年龄(6.10±1.87)岁；病程2～10年，平均病程(2.10±0.40)年。两组患儿在年龄、性别、病程等基础资料方面，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(尹静华)
关键词：孟鲁司特钠；小儿哮喘；肺功能指标
中图分类号：R725.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.09.043
, http://www.100md.com
文章编号：1006-1959(2018)09-0138-02
Abstract：Objective To study the clinical efficacy of montelukast sodium in treating asthma in children.Methods 120 children with asthma treated in our hospital from October 2016 to November 2017 were randomly divided into control group and observation group， 60 cases each.The control group was treated with routine symptomatic treatment.The observation group was treated with montelukast sodium.The efficacy of the two groups was compared， the clinical symptoms disappeared，the lung function indicators and adverse reactions were compared.Results The effective rate was 96.67% in the observation group，which was 78.33% higher than that in the control group，the difference was statistically significant(P<0.05).The cough in the observation group， the wheezing of the lungs，and the disappearance of asthma were all shorter than those in the control group，the difference was statistically significant(P<0.05).The observation group VCmax，FEV1，FEV1/FVC improved better than the control group，the difference was statistically significant(P<0.05). During the treatment and observation period，no serious adverse reactions occurred in both groups of children.Conclusion Montelukast sodium is effective in the treatment of children with asthma.It can shorten the time of clinical symptoms and improve the lung function of children.It is worthy of clinical promotion and application.
, 百拇医药
Key words：Montelukast sodium；Children with asthma；Lung function index
哮喘(asthma)是由炎癥因子等多种原因引起的变态性反应，是小儿常见的呼吸道疾病[1]。临床患儿多伴有胸闷、喘息、咳嗽等症状，严重影响患儿的健康和生活质量。小儿哮喘急性发作时患儿会出现严重呼吸困难，且该疾病容易反复，影响患儿的健康生长，临床应给予有效治疗。小儿哮喘的常规治疗采用止咳、平喘等对症治疗，临床效果有限，治疗疗程长。有关研究表明，采用孟鲁司特钠治疗小儿哮喘具有理想的治疗效果[2]。本次研究选取2016年10月～2017年11月在我院治疗的120例小儿哮喘临床资料，分析孟鲁司特钠治疗小儿哮喘的临床有效性，现报告如下。
1资料与方法
1.1一般资料 回顾分析2016年10月～2017年11月在重庆市丰都县中医院治疗的120例小儿哮喘临床资料。按照随机数字表法分为对照组和观察组，每组60例。对照组中，男34例，女26例；年龄3～14岁，平均年龄(5.98±2.10)岁；病程2～8年，平均病程(2.34±0.40)年。观察组中，男32例，女28例；年龄2～14岁，平均年龄(6.10±1.87)岁；病程2～10年，平均病程(2.10±0.40)年。两组患儿在年龄、性别、病程等基础资料方面，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(尹静华)